Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Al | INSM Message Board Posts

Insmed Incorporated

  INSM website

INSM   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  46236 of 46870  at  6/13/2019 8:37:54 AM  by

bohemian


 In response to msg 46233 by  b_leaguered
view thread

Re: Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)

SVRA might be a good buy under three. They missed the primary endpoint, but hit the secondary. Reminds me of another stock that I’ve followed for years.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 150
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
46237 Re: Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP) JAD9000 0 6/13/2019 8:41:52 AM
46238 Re: Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP) zake1 0 6/13/2019 8:46:43 AM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...